Pfizer Receives Prix Galien USA Award On Account Of Chantix Efficacy
Date: 3rd October 2007
Pfizer Incl., the USA based drug manufacturing company was recently awarded the New York Biotechnology Association (NYBA) sponsored Prix Galien USA prize at the inauguration of the Prix Galien USA function and altogether it is also known that Pfizer has received the award due to the effectiveness shown by its anti-smoking drug Chantix in accelerating smoking cessation.
Regarding the selection of Pfizer Incl. for the award, Nathan Tinker, Executive Director of New York Biotechnology Association pronounces that NYBA is specifically elated for the reason that Pfizer has been granted the award and further on behalf of all NYBA members and board directors, he extends congratulation to Pfizer for receiving the award.
Moreover Nathan Tinker also spelled out that the Prix Galien USA prize is regarded in the pharmaceutical industry to be synonymous with the noble prize in and around Europe .